Berberine as Adjuvant Treatment for Schizophrenia Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

April 25, 2018

Primary Completion Date

December 30, 2020

Study Completion Date

January 4, 2021

Conditions
SchizophreniaSchizophrenia Spectrum and Other Psychotic DisordersMetabolic Syndrome x
Interventions
DRUG

Berberine

Berberine tablets, 0.3g every time, two times daily

DRUG

Placebos

Placebo tablets, 0.3g every time, two times daily

DRUG

Antipsychotic Agents

Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.

Trial Locations (1)

Unknown

Castle Peak Hospital - The Department of General Adult Psychiatry, Tuenmen

All Listed Sponsors
collaborator

Queen Mary Hospital, Hong Kong

OTHER

collaborator

Kowloon Hospital, Hong Kong

OTHER

collaborator

Castle Peak Hospital

OTHER_GOV

collaborator

Zhejiang Provincial Tongde Hospital

OTHER

lead

The University of Hong Kong

OTHER

NCT02983188 - Berberine as Adjuvant Treatment for Schizophrenia Patients | Biotech Hunter | Biotech Hunter